Trials / Completed
CompletedNCT04978051
Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection
Randomized, Open, Multicenter Phase II Clinical Trial, Proof of Concept, to Evaluate Efficacy and Safety of Icatibant in Hospitalized Patients With SARS-COV-2 (COVID-19) Without Assisted Ventilation Compared With Standard Care
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Sebastian Videla · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To study the efficacy and safety of icatibant in adult patients admitted to hospitalization units for pneumonia caused by COVID-19, without mechanical ventilation, 10±1 days after starting treatment or discharge from hospital if this occurs before 10 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Firazyr | Icatibant 10 MG/ML Prefilled Syringe |
| OTHER | SoC | The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options |
Timeline
- Start date
- 2021-04-12
- Primary completion
- 2021-11-30
- Completion
- 2022-03-17
- First posted
- 2021-07-27
- Last updated
- 2022-08-03
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04978051. Inclusion in this directory is not an endorsement.